BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33452163)

  • 21. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention.
    Frech TM; Khanna D; Maranian P; Frech EJ; Sawitzke AD; Murtaugh MA
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S22-5. PubMed ID: 21586214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.
    Luebker S; Frech TM; Assassi S; Gordon JK; Bernstein EJ; Steen VD; Shah AA; Hummers LK; Richardson C; Khanna D; Castelino FV; Chung L; Hant FN; Shanmugam VK; VanBuren JM; Alvey J; Harding M; Sandorfi N
    Clin Exp Rheumatol; 2023 Aug; 41(8):1632-1638. PubMed ID: 37497718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal manifestations on impaired quality of life in systemic sclerosis.
    Yang H; Xu D; Li MT; Yao Y; Jin M; Zeng XF; Qian JM
    J Dig Dis; 2019 May; 20(5):256-261. PubMed ID: 30838807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study.
    Frech T; Hays RD; Maranian P; Clements PJ; Furst DE; Khanna D
    Rheumatology (Oxford); 2011 Jul; 50(7):1280-7. PubMed ID: 21324979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measuring response in the gastrointestinal tract in systemic sclerosis.
    Khanna D; Nagaraja V; Gladue H; Chey W; Pimentel M; Frech T
    Curr Opin Rheumatol; 2013 Nov; 25(6):700-6. PubMed ID: 24047604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.
    Taş YM; Derviş Hakim G; Keskinoğlu P; Kenar G; Yarkan H; Zengin B; Can G; Önen F; Akkoç N; Birlik M; Akarsu M
    Turk J Gastroenterol; 2019 Mar; 30(3):234-241. PubMed ID: 30541712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument.
    Khanna D; Hays RD; Park GS; Braun-Moscovici Y; Mayes MD; McNearney TA; Hsu V; Clements PJ; Furst DE
    Arthritis Rheum; 2007 Oct; 57(7):1280-6. PubMed ID: 17907224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Patient and Physician Assessments of Gastrointestinal Disease Activity in Systemic Sclerosis.
    Ross L; Proudman S; Walker J; Stevens W; Ferdowsi N; Quinlivan A; Morrisroe K; Baron M; Nikpour M
    J Rheumatol; 2023 Apr; 50(4):519-525. PubMed ID: 36379565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Ferreira PL; Genrinho I; Santiago T; Carones A; Mazeda C; Barcelos A; Beirão T; Costa F; Santos I; Couto M; Rato M; Terroso G; Monteiro P
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal symptom severity and progression in systemic sclerosis.
    van Leeuwen NM; Boonstra M; Fretheim H; Brunborg C; Midtvedt Ø; Garen T; Molberg Ø; Huizinga TWJ; de Vries-Bouwstra JK; Hoffman-Vold AM
    Rheumatology (Oxford); 2022 Oct; 61(10):4024-4034. PubMed ID: 35238377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
    Baron M; Hudson M; Steele R; Lo E;
    J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nutritional status and gastrointestinal symptoms in systemic sclerosis patients.
    Murtaugh MA; Frech TM
    Clin Nutr; 2013 Feb; 32(1):130-5. PubMed ID: 22770637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Furst DE; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Hays RD
    J Rheumatol; 2011 Sep; 38(9):1920-4. PubMed ID: 21724699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and validation of Hebrew version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0.
    Ozeri D; Peretz S; Oppenheim A; Watad A; Lidar M; Braun-Moscovici Y
    J Scleroderma Relat Disord; 2023 Feb; 8(1):31-35. PubMed ID: 36743811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of probiotics on gastrointestinal symptoms and immune parameters in systemic sclerosis: a randomized placebo-controlled trial.
    Marighela TF; Arismendi MI; Marvulle V; Brunialti MKC; Salomão R; Kayser C
    Rheumatology (Oxford); 2019 Nov; 58(11):1985-1990. PubMed ID: 31056685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Gorga M; Mihai C; Soare AM; Dobrotă R; Gherghe AM; Stoica V
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S61-7. PubMed ID: 26316302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem.
    Ntoumazios SK; Voulgari PV; Potsis K; Koutis E; Tsifetaki N; Assimakopoulos DA
    Semin Arthritis Rheum; 2006 Dec; 36(3):173-81. PubMed ID: 17045629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis.
    Maclean RH; Ahmed F; Ong VH; Murray CD; Denton CP
    J Rheumatol; 2023 Jul; 50(7):907-915. PubMed ID: 36792109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis.
    Rosato E; Gigante A; Pellicano C; Villa A; Iannazzo F; Alunni Fegatelli D; Muscaritoli M
    Clin Rheumatol; 2022 Jun; 41(6):1687-1696. PubMed ID: 35149929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of early asymptomatic esophageal dysfunction in systemic sclerosis using a new scintigraphic grading method.
    Kaye SA; Siraj QH; Agnew J; Hilson A; Black CM
    J Rheumatol; 1996 Feb; 23(2):297-301. PubMed ID: 8882035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.